Page 158 - Q26 -

¥ÿ≈æ“À

and user-friendly. Countries may try to create incentives for the patent holders

to disclose all patents they have on a specific medicine.

Seventh, non-patent barrier to the accessibility to pharmaceuticals,

such as the measure of quality assurance which significantly extend the period

of patent exclusivity on drugs, should be avoided. In other words, the

production of generic medicines should be allowed during the period of safety

monitoring for pipeline production.

Last, it is worth mentioning that TRIPS flexibilities cannot be

functioned unless the stream of the FTAs containing TRIPS-plus provisions and

unilateral pressure from the developed countries is curbed. The developing

countries should attempt to deny legal obligations that reject the TRIPS

flexibilities created through bilateral or multilateral negotiations with the
developed countries.

Bibliography

Ahmadiani, Saeed, and Shekoufeh Nikfar. çDARU Journal of Pharmaceutical

Sciences.é†Challenges of Access to Medicine and the Responsibility of

Pharmaceutical Companies: a Legal Perspective, 2016.

Burdon, M., and K. Sloper. çThe Art of Using Secondary Patents to Improve

Protection.醋Journal of Medical Marketing, 2003, 226-28.

Correa, Carlos.†Guidelines for the Examination of Pharmaceutical Patents:

Developing a Public Health Perspective. ICTSD-UNCTAD, 2007.

European Commission.†Pharmaceutical Sector Inquiry: Final Report, 2009, 189.

¡°√“§¡ - ‡¡…“¬π ÚıˆÛ 147